secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0000950170-22-006779
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference
--------------------------------------------------------------------------------

- Management presented two posters at PEGS Boston on May 2-5, 2022.
- JANX007 is a PSMA-targeted TRACTr for prostate cancer; JANX008 is EGFR-targeted for solid tumors.
- Data is preclinical; no clinical results or financial guidance disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/0000950170-22-006779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022006779/janx-20220502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-006779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer